Immuno-oncology programs
GPCRs constitute strategic targets mediating immunosuppression. The company exploits its expertise in the field to move forward small molecule and antibody based-assets toward the clinic.
immuno-oncology
A2aR/A2bR antagonist
EP4 receptor antagonist ( DT-9081 )
Anti-CCR8 antibody
Undisclosed GPCR targets